rethink-alz.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | RethinkALZ and RefocusALZ Clinical Research Studies | |
| Description | PAVING THE WAY FOR FUTURE The rethinkALZ and refocusALZ clinical research studies are currently enrolling patients ages 50-87 who are diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 50.16.80.42 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
rethink-alz.com Valuation
|
US$851,174
Last updated: 2023-05-15 05:52:12
rethink-alz.com has Semrush global rank of 12,434,958. rethink-alz.com has an estimated worth of US$ 851,174, based on its estimated Ads revenue. rethink-alz.com receives approximately 98,213 unique visitors each day. Its web server is located in United States, with IP address 50.16.80.42. According to SiteAdvisor, rethink-alz.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$851,174 |
| Daily Ads Revenue | US$786 |
| Monthly Ads Revenue | US$23,571 |
| Yearly Ads Revenue | US$282,852 |
| Daily Unique Visitors | 6,548 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| rethink-alz.com. | A | 599 | IP: 50.16.80.42 |
| rethink-alz.com. | NS | 3600 | NS Record: ns05.domaincontrol.com. |
| rethink-alz.com. | NS | 3600 | NS Record: ns06.domaincontrol.com. |
HtmlToTextCheckTime:2023-05-15 05:52:12
| About The Studies About Alzheimer’s Disease Study Locations FAQs Complete Pre-Screener PAVING THE WAY FOR FUTURE GENERATIONS If you or a loved one has been diagnosed with Alzheimer’s disease, or your physician suspects it may be Alzheimer’s disease, you or they may be eligible to participate in one of two new clinical trials to help advance the treatment of Alzheimer’s disease. Complete the Pre-Screener RethinkALZ and RefocusALZ Clinical Trials RethinkALZ and RefocusALZ are the names of two new clinical trials for Alzheimer’s disease. The purpose of these trials is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition. Clinical trials are research studies in which people volunteer to help find |
HTTP Headers
HTTP/1.1 302 Redirect Content-Length: 147 Content-Type: text/html; charset=UTF-8 Location: https://rethink-alz.com/ Server: Microsoft-IIS/10.0 X-Powered-By: ASP.NET Date: Fri, 24 Dec 2021 19:19:07 GMT HTTP/2 200 content-length: 12234 content-type: text/html last-modified: Tue, 21 Dec 2021 10:13:02 GMT accept-ranges: bytes etag: "0cb385653f6d71:0" server: Microsoft-IIS/10.0 x-powered-by: ASP.NET date: Fri, 24 Dec 2021 19:19:07 GMT |
rethink-alz.com Whois Information
Domain Name: RETHINK-ALZ.COM Registry Domain ID: 2619124816_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2021-11-05T20:19:03Z Creation Date: 2021-06-12T17:04:40Z Registry Expiry Date: 2024-06-12T17:04:40Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS05.DOMAINCONTROL.COM Name Server: NS06.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-29T07:51:36Z <<< |